Annovis Bio, Inc.

NYSE:ANVS 株式レポート

時価総額：US$90.5m

Annovis Bio マネジメント

マネジメント 基準チェック /24

Annovis Bioの CEO はMaria Maccecchiniで、 May2008年に任命され、 の在任期間は 16.5年です。 の年間総報酬は$ 2.15Mで、 31.1%給与と68.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の7.96%を直接所有しており、その価値は$ 7.21M 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と8.8年です。

主要情報

Maria Maccecchini

最高経営責任者

US$2.1m

報酬総額

CEO給与比率31.1%
CEO在任期間16.5yrs
CEOの所有権8.0%
経営陣の平均在職期間1.3yrs
取締役会の平均在任期間8.8yrs

経営陣の近況

Recent updates

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Oct 17

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Sep 27

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Jul 08

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Jun 30

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

May 02

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Feb 12

Annovis And Alzheimer's Disease: The Best-Laid Plans

Jan 30

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Jan 20

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Oct 16

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Sep 08
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Jun 28

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Feb 08

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Jan 28
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Jan 25

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Oct 06

We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Sep 15
We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Annovis Bio announces publication of three U.S. patents covering lead asset

Sep 13

Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate

Aug 24

Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate

Jul 07

Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

May 14
Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Feb 10
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

Feb 23
Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Jan 01
We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

CEO報酬分析

Annovis Bio の収益と比較して、Maria Maccecchini の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$2mUS$668k

-US$56m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$3mUS$636k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$9mUS$510k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$420k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$120kUS$120k

-US$991k

Sep 30 2019n/an/a

-US$958k

Jun 30 2019n/an/a

-US$841k

Mar 31 2019n/an/a

-US$715k

Dec 31 2018US$155kUS$120k

-US$714k

報酬と市場: Mariaの 総報酬 ($USD 2.15M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Mariaの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Maria Maccecchini (73 yo)

16.5yrs

在職期間

US$2,145,852

報酬

Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Maria Maccecchini
Founder16.5yrsUS$2.15m7.96%
$ 7.2m
Mark White
Chief Business Officer & Directorless than a yearUS$135.43k0.44%
$ 401.3k
Cheng Fang
Senior Vice President of Research & Development2.8yrsデータなしデータなし
Eve Damiano
Senior Vice President of Regulatory Operations2.8yrsデータなしデータなし
Melissa Gaines
Senior Vice President of Clinical Operations1.3yrsデータなしデータなし
Blake Jensen
Head of Qualityless than a yearデータなしデータなし
Hilda Maibach
Senior Vice President of Statisticsless than a yearデータなしデータなし

1.3yrs

平均在職期間

経験豊富な経営陣: ANVSの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Maria Maccecchini
Founder16.5yrsUS$2.15m7.96%
$ 7.2m
Mark White
Chief Business Officer & Director8.8yrsUS$135.43k0.44%
$ 401.3k
Michael M. Hoffman
Independent Chairman of the Board10.8yrsUS$153.92k11.88%
$ 10.8m
Jeffrey Cummings
Chief Medical Advisor & Member of Scientific Advisory Boardno dataデータなしデータなし
Gregory Petsko
Member of Scientific Advisory Board7.8yrsデータなしデータなし
Reid McCarthy
Independent Director3.6yrsUS$143.92k0.053%
$ 47.9k
Sidney Strickland
Chairman of Scientific Advisory Board7.8yrsデータなしデータなし
Claudine Bruck
Independent Director9.8yrsUS$135.43k0.048%
$ 43.1k

8.8yrs

平均在職期間

71.5yo

平均年齢

経験豊富なボード: ANVSの 取締役会 は 経験豊富 であると考えられます ( 8.8年の平均在任期間)。